CARTITUDE-1 Efficacy Findings
Panelists discuss how the efficacy outcomes from CARTITUDE-1, including a substantial progression-free survival (PFS) benefit, highlight the transformative impact of deep, sustained minimal residual disease (MRD)-negative responses.
Efficacy data from CARTITUDE-1 show a median PFS of 34.9 months—dramatically better than the 4.6 months seen in external control cohorts. Importantly, the median follow-up at the time was more than 33 months.
Patients with sustained MRD negativity had not reached median PFS at the time of reporting. Approximately 75% of such patients remained progression free at 30 months.
These results underscore the depth and durability of response achieved with ciltacabtagene autoleucel, particularly in a refractory population. Sustained MRD negativity correlates strongly with favorable long-term outcomes, suggesting potential for long-term disease control or cure.
